FidoCure

About FidoCure by the One Health Company: The One Health Company is the first to bring the latest advances in individualized precision medicine to canine cancer patients with its FidoCure® Next Generation DNA Sequencing Test. The FidoCure platform creates tailored treatment plans for canine cancer patients by applying sophisticated diagnostics and treatments approved for human use. FidoCure has ushered in the era of precision veterinary oncology by assembling the world's largest canine cancer genomics database, which is used to ensure that pet dogs have access to the latest advances in cancer care. You can view our peer reviewed research in Nature Precision Oncology Journal and Nature Scientific Reports. The One Health Company is backed by premier biotech investors including Polaris Ventures, A16Z, and YCombinator. Learn more at www.fidocure.com.